References of "Ehx, Grégory"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailImmune Recovery after Allogeneic Hematopoietic Stem Cell Transplantation following Flu-TBI versus TLI-ATG Conditioning
HANNON, Muriel ULg; BEGUIN, Yves ULg; Ehx, Grégory ULg et al

in Clinical Cancer Research : An Official Journal of the American Association for Cancer Research (in press)

Purpose: A conditioning regimen for allogeneic hematopoietic cell transplantation (HCT) combining total lymphoid irradiation (TLI) plus anti-thymocyte globulin (ATG) has been develop to induce graft ... [more ▼]

Purpose: A conditioning regimen for allogeneic hematopoietic cell transplantation (HCT) combining total lymphoid irradiation (TLI) plus anti-thymocyte globulin (ATG) has been develop to induce graft-versus-tumor effects without graft-versus-host disease (GVHD). Experimental Design: We compared immune recovery in 53 patients included in a phase II randomized study comparing nonmyeloablative HCT following either fludarabine plus 2 Gy total body irradiation (TBI arm, n=28) or 8 Gy TLI plus anti-thymocyte globulin (TLI arm, n=25). Results: In comparison to TBI patients, TLI patients had a similarly low 6-month incidence of grade II-IV acute GVHD, a lower incidence of moderate/severe chronic GVHD (P=0.02), a higher incidence of CMV reactivation (P<0.001), and a higher incidence of relapse (P=0.01). While recovery of total CD8+ T cells was similar in the two groups, with median CD8+ T cell counts reaching the normal values 40-60 days after allo-HCT, TLI patients had lower percentages of naïve CD8 T cells. Median CD4+ T cell counts did not reach the lower limit of normal values the first year after allo-HCT in the two groups. Further, CD4+ T cell counts were significantly lower in TLI than in TBI patients the first 6 months after transplantation. Interestingly, while median absolute regulatory T cell (Treg) counts were comparable in TBI and TLI patients, Treg/naïve CD4+ T cell ratios were significantly higher in TLI than in TBI patients the 2 first years after transplantation. Conclusions: Immune recovery differs substantially between these two conditioning regimens possibly explaining the different clinical outcomes observed (NCT00603954). [less ▲]

Detailed reference viewed: 54 (8 ULg)
Full Text
See detailAzacytidine prevents experimental sclerodermic chronic graft-versus-host disease
Fransolet, Gilles ULg; Ehx, Grégory ULg; SOMJA, Joan ULg et al

Poster (2015, January 30)

Introduction: Graft-versus-host disease (GVHD) remains one major complication of allogeneic hematopoietic stem cell transplantation (HSCT). Following unmanipulated peripheral-blood stem cell ... [more ▼]

Introduction: Graft-versus-host disease (GVHD) remains one major complication of allogeneic hematopoietic stem cell transplantation (HSCT). Following unmanipulated peripheral-blood stem cell transplantation, 60% of the patients experience chronic GVHD while approximately 15% of them develop a sclerodermic form of chronic GVHD characterized by multiple organ fibrosis and loss of skin elasticity. Regulatory T cells (Tregs) play a pivotal role in the pathology of chronic GVHD by inhibiting alloreactive conventional T cells. Several studies have shown the hypomethylating agent Azacytidine (Aza) can demethylate the master transcription factor of Treg (Forkhead box protein 3 factor, FoxP3), thus promoting Treg differentiation of conventional T cells. This work investigates the impact of Aza in a classical murine model of sclerodermic chronic GVHD (B10.D2  BALB/cJ). Methods: Lethally irradiated BALB/cJ recipient mice were injected with 107 bone marrow cells + 7.107splenocytes from B10.D2 donor mice. Recipients were treated with subcutaneous injections of Aza at the dose of 0,5 or 2 mg/kg every two days from day 10 to 30 following transplantation. Mice GVHD was evaluated with five criteria (weight loss, activity, fibrosis, hair loss and mice posture; 0-1-2 points/criteria). Mice were sacrificed at a score of 8/10 (or > 20% weight loss). Results: Mice treated with Aza 0.5 mg/kg (n = 14) or 2 mg/kg (n = 17) had significant lower clinical scores compared to control ones (n = 15) after treatment. FACS analysis showed a higher proportion of Treg among CD4+ T cells in the blood of Aza 2 mg/kg mice than in control mice (P = 0.047), as well as a higher percentage of Tregs expressing the KI67 proliferative marker on the same day (P = 0.0005). Finally, analyses of the cellular blood components with Cell-dyn demonstrated that Aza 2 mg/kg treated mice were significantly lymphopenic as compared to control mice (P = 0.05). Conclusion : Aza prevented sclerodermic GVHD in this classical murine model of chronic GVHD. [less ▲]

Detailed reference viewed: 19 (0 ULg)
See detailAzacytidine augments regulatory T cells and prevents experimental xenogeneic graft-versus-host disease.
Ehx, Grégory ULg

Conference (2015, January 30)

The demethylating agent 5-azacytidine (AZA) has proven its efficiency in myeloid malignancies treatment. Recently, several studies have shown that AZA also presents an immunomodulatory activity, mainly ... [more ▼]

The demethylating agent 5-azacytidine (AZA) has proven its efficiency in myeloid malignancies treatment. Recently, several studies have shown that AZA also presents an immunomodulatory activity, mainly through the induction of regulatory T cells (Treg) differentiation from conventional T cells. Treg promotion is a promising treatment option for graft-versus-host disease (GVHD) following hematopoietic stem cell transplantation. In this way, AZA has been shown to reduce GVHD in mouse-to-mouse transplantation models. However, the impact of AZA on human GVHD remains elusive as well as its effects on human Treg and on the other T cell subsets in vivo. Here we report AZA impact on GVHD in a xeno-transplantation model of the disease and describe the overall effects of the drug on human T cells in vivo. When administered to NSG mice receiving 2.107 human PBMC intravenously, AZA successfully ameliorated both survival (p < 0.001) and GVHD score. Flow cytometry analyses showed that this improvement may be mediated through an anti-proliferative effect of AZA on human T cells while these cells presented an increased activation state. We also observed a significant decrease of Th1 and 2 differentiation, assessed by RT-qPCR and cytokines secretion assays, and a reduced production of granzyme B and perforin 1 by cytotoxic T cells. As expected, AZA dramatically augmented Treg frequency while we could also observe a promotion of their IL-2 mediated proliferation over conventional T cells. Interestingly, Th17 frequency was not affected by AZA, therefore increasing the balance Treg/Th17. Finally our data suggest that AZA-induced Treg may have an improved suppressive activity and present long-term stability in vivo. Altogether our findings suggest that AZA may be a promising treatment option for GVHD in the clinical setting. [less ▲]

Detailed reference viewed: 11 (2 ULg)
Full Text
Peer Reviewed
See detailLiver proteomic response to hypertriglyceridemia in human-apolipoprotein C-III transgenic mice at cellular and mitochondrial compartment levels
Ehx, Grégory ULg; Gerin, Stéphanie ULg; Mathy, Grégory et al

in Lipids in Health and Disease (2014), 13

Background: Hypertriglyceridemia (HTG) is defined as a triglyceride (TG) plasma level exceeding 150 mg/dl and is tightly associated with atherosclerosis, metabolic syndrome, obesity, diabetes and acute ... [more ▼]

Background: Hypertriglyceridemia (HTG) is defined as a triglyceride (TG) plasma level exceeding 150 mg/dl and is tightly associated with atherosclerosis, metabolic syndrome, obesity, diabetes and acute pancreatitis. The present study was undertaken to investigate the impact of hypertriglyceridemia on the mitochondrial, sub-mitochondrial and cellular proteomes in the hepatocytes of a hypertriglyceridemic transgenic mouse model overexpressing the human apolipoproteinC-III. Methods: Quantitative comparative proteomics (2D-DIGE) was carried out in both “low-expressor” (LE) and “high-expressor” (HE) mice, respectively exhibiting moderate and severe HTG, to characterize the effect of the TG plasma level on the proteomic response. Results: The mitoproteome analysis revealed the occurrence of a large-scale adaptation in transgenic mice consisting of a general down-regulation of matricial proteins and up-regulation of inner membrane proteins. Remarkably, the magnitude of these proteomic changes appears to strongly depend on the TG plasma level. Altogether, our different analyses indicate that, in HE mice, the capacity of several metabolic pathways is altered to promote the availability of acetyl-CoA, glycerol-3-phosphate, ATP and NADPH for de novo TG biosynthesis. The up-regulation of several cytosolic ROS detoxifying enzymes also tend to confirm that the cytoplasm of HTG mice is subjected to oxidative stress as previously stated. The up-regulation of cytosolic ferritin indicates that iron over-accumulation could take place in the cytosol of HE mice hepatocytes and contribute to (i) enhance oxidative stress and (ii) promote cellular proliferation. Conclusions: The present analyses demonstrate that important TG dose-responsive metabolic adaptations are set up in human apolipoproteinC-III-overexpressing mice. Our results indicate that these adaptations could support the higher TG production rates which have been previously reported in this HTG model, and also suggest that cytosolic oxidative stress may result from FFA over-accumulation, iron overload and enhanced activity of some ROS-producing catabolic enzymes. [less ▲]

Detailed reference viewed: 48 (13 ULg)
See detailXenogeneic GVHD in NSG mice: focus on rapamycin
Ehx, Grégory ULg

Conference (2014, April 11)

Detailed reference viewed: 27 (7 ULg)
See detailImmunomodulatory effects of Rapamycin in xenogeneic GVHD
Ehx, Grégory ULg

Poster (2014, January 31)

Graft-versus-host disease (GVHD) remains a major cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation (HSCT). Several studies have shown that rapamycin (RAPA), an mTOR ... [more ▼]

Graft-versus-host disease (GVHD) remains a major cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation (HSCT). Several studies have shown that rapamycin (RAPA), an mTOR inhibitor with immunosuppressive properties, may reduce GVHD severity and mortality, notably by favoring regulatory T cells (Tregs) proliferation in vivo and in vitro. However, very few data have been reported about the global impact of this drug on the immune system in the context of GVHD. The present work investigates the cellular mechanisms by which RAPA delays death from xenogeneic GVHD induced by peripheral blood mononuclear cells infusion in NSG mice. Our results show that RAPA injections significantly delay death from xenogeneic GVHD and reduce disease severity. Flow cytometric analyses highlighted a strong reduction of human cells chimerism in mice together with higher CD4+/CD8+ T cells balance due to a lower proliferation of CD8+ T cells. In addition, the frequencies of naive CD4+ and CD8+ T cells were higher and the CD4+ T cells showed a reduced effector phenotype (CD45RO+CD27-). Tregs were positively affected as RAPA up-regulated their expression of Bcl-2 and Ki67 as well as their STAT5 phosphorylation level, leading to higher Treg frequency in treated mice. Altogether these data demonstrate that RAPA delays xenogeneic GVHD by lowering human chimerism and effector CD4+ frequency as well as promoting Tregs. [less ▲]

Detailed reference viewed: 38 (10 ULg)
Full Text
See detailImmunomodulatory effects of Rapamycin in xenogeneic GVHD
Ehx, Grégory ULg; HANNON, Muriel ULg; DUBOIS, Sophie ULg et al

Poster (2014, January 27)

Detailed reference viewed: 23 (12 ULg)
Full Text
Peer Reviewed
See detailThinking out of the box - New approaches to controlling GVHD
Baron, Frédéric ULg; Humblet-Baron, Stéphanie; Ehx, Grégory ULg et al

in Current Hematologic Malignancy Reports (2014), 9

Graft-versus-host disease (GVHD) remains a major limitation of allogeneic hematopoietic cell transplantation (allo-HCT). Despite major advances in the understanding of GVHD pathogenesis, standard GVHD ... [more ▼]

Graft-versus-host disease (GVHD) remains a major limitation of allogeneic hematopoietic cell transplantation (allo-HCT). Despite major advances in the understanding of GVHD pathogenesis, standard GVHD prophylaxis regimens continue to bebased on the combination of a calcineurin inhibitor with an antimetabolite, while first line treatmentsstill relies on high-dose corticosteroids. Further, no second line treatment has emerged thus far in acute or chronic GVHD patients who failed on corticosteroids. After briefly reviewing current standards of GVHD prevention and treatment, this article will discuss recent approaches that might change GVHD prophylaxis / treatment in the next decades, with a special focus on recently developed immunoregulatory strategies based on infusion of mesenchymal stromal or regulatory T-cells, or on injection of lowdose interleukin-2. [less ▲]

Detailed reference viewed: 65 (18 ULg)
See detailEtude protéomique de l'incidence d'une hypertriglycéridémie sur le métabolisme hépatique de la souris
Ehx, Grégory ULg

Master's dissertation (2011)

L’hypertriglycéridémie est une pathologie largement répandue chez l’homme sédentarisé. Elle se définit comme un taux plasmatique de triglycérides (TAG) anormalement élevé (supérieur à 200 mg/dl). La ... [more ▼]

L’hypertriglycéridémie est une pathologie largement répandue chez l’homme sédentarisé. Elle se définit comme un taux plasmatique de triglycérides (TAG) anormalement élevé (supérieur à 200 mg/dl). La souris transgénique HuApoC-III est un animal modèle idéal pour l’étude de l’hypertriglycéridémie indépendamment des effets confondants qui y sont généralement associés (en particulier l’obésité et la résistance à l’insuline). En effet, elles sont hypertriglycéridémiques mais ne sont ni obèses ni résistantes à l’insuline. Dans la continuité d’une étude des adaptations mitoprotéomiques hépatique à une hypertriglycéridémie sévère (taux de TAG supérieur à 500 mg/dl) récemment menée par notre laboratoire, nous avons caractérisé par une technique de protéomique comparative, le 2DDIGE, les adaptations protéomiques de la membrane interne mitochondriale et du protéome cellulaire à ce même type d’hypertriglycéridémie, chez la souris HuApoC-III. Comme prédit lors de notre étude antérieure, le protéome de la membrane interne s’est avéré ne présenter aucune modification de sa composition entre les souris HuApoC-III et sauvages. Comme il a été rapporté que les souris HuApoC-III présentent une vitesse de respiration mitochondriale à l’état III sur succinate similaire à celle des souris sauvages, cette invariance de la composition protéique de la membrane interne pourrait refléter des altérations de sa composition lipidique ou de sa structure. L’analyse du protéome cellulaire total a permis de confirmer l’augmentation de la capacité du catabolisme des acides aminés et de la glycolyse suggérée par nos résultats antérieurs. Cette augmentation, accompagnée de l’augmentation de la capacité de la β- oxydation également décrite antérieurement, permettrait d’augmenter le taux de production d’acétyl-CoA, de glycérol-3-phosphate et d’ATP fin de supporter la production élevée de TAG des hépatocytes des souris HuApoC-III. Cette analyse a par ailleurs révélé que les hépatocytes des souris HuApoC-III présentent un stress oxydatif cytoplasmique, une probable accumulation de fer intracytoplasmique et une prolifération accrue. Ce stress oxydatif pouvant induire des lésions cellulaires et tissulaires ainsi que l’inflammation du foie, nous proposons que les souris HuApoC-III présentent une fibrose hépatique. [less ▲]

Detailed reference viewed: 126 (65 ULg)